Phenyl salicylate

Endpoint summary

Description of key information

As reported by Marchand B.et al.in 1982 [1], the sensitizing properties of salol (phenyl salicylate) were not well-documented. The only studies of experimental sensitization were those of Kligman in his Maximization test. In these studies the absence of sensitization in man (on 25 patients) was concluded, and salol was classed in group I (weak or nonallergens). The study of Marchand B.et al.[1], shows the sensitizing power of phenyl salicylates in man, a result which was not expected from the maximization test. This study shows clearly that experimental sensitization to salol in guinea pigs is also feasible.

 

Therefore, the substance is classified as Skin Sens. 1 H317.

[1] Marchand B., Barbier P., Ducombs G., Foussereau J., Martin P., Benezra C. Allergic contact dermatitis to various salols (phenyl salicylates). A structure-activity relationship study in man and in animal (guinea pig). Archives of Dermatological Research. March 1981, Volume 272, Issue 1–2, pp 61–66.

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records

Reference

Endpoint:

skin sensitisation, other

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

4 (not assignable)

Rationale for reliability incl. deficiencies:

abstract

As reported by Marchand B.et al.in 1982, the sensitizing properties of salol (phenyl salicylate) were not well-documented. The only studies of experimental sensitization were those of Kligman in his Maximization test. In these studies the absence of sensitization in man (on 25 patients) was concluded, and salol was classed in group I (weak or nonallergens). This study shows the sensitizing power of phenyl salicylates in man, a result which was not expected from the maximization test. This study shows clearly that experimental sensitization to salol in guinea pigs is also feasible.

 

Interpretation of results:

Category 1 (skin sensitising) based on GHS criteria

Conclusions:

The sensitizing properties of salol (phenyl salicylate) were not well-documented. The only studies of experimental sensitization were those of Kligman in his Maximization test. In these studies the absence of sensitization in man (on 25 patients) was concluded, and salol was classed in group I (weak or nonallergens). This study shows the sensitizing power of phenyl salicylates in man, a result which was not expected from the maximization test. This study shows clearly that experimental sensitization to salol in guinea pigs is also feasible.

Therefore, the substance is classified as Skin Sens. 1 H317.

Endpoint conclusion

Endpoint conclusion:

adverse effect observed (sensitising)

Respiratory sensitisation

Endpoint conclusion

Endpoint conclusion:

no study available